MEK2 Protein, Human, Recombinant (GST)

カタログ番号 TMPY-04544

別名: mitogen-activated protein kinase kinase 2, FLJ26075, MKK2, CFC4, PRKMK2, MEK2, MAPKK2

Dual specificity mitogen-activated protein kinase kinase 2, also known as MAP kinase kinase 2, MAPKK2, ERK activator kinase 2, MAPK / ERK kinase 2, MEK2 and MAP2K2, is a member of the protein kinase superfamily, STE Ser/Thr protein kinase family and MAP kinase kinase subfamily. MAP2K2 / MEK2 contains one protein kinase domain. MEK1 and MEK2 (also known as MAP2K1 and MAP2K2, respectively) are evolutionarily conserved, dual-specificity kinases that mediate Erk1 and Erk2 activation during adhesion and growth factor signaling. MAP2K1 / MEK1 is a crucial modulator of Mek and Erk signaling and have potential implications for the role of MEK1 and MEK2 in tumorigenesis. MAP2K2 / MEK2 catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. It also activates the ERK1 and ERK2 MAP kinases. Defects in MAP2K2 are a cause of Cardiofaciocutaneous Syndrome (CFC Syndrome) which is characterized by a distinctive facial appearance, heart defects, and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects, and hypertrophic cardiomyopathy.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy

All products from TargetMol are for Research Use Only. Not for Human or Veterinary or Therapeutic Use.

MEK2 Protein, Human, Recombinant (GST)

パッケージサイズ	在庫状況	単価(税別)
50 μg	約5 days	￥ 91,500

バルクのお問い合わせ

DATASHEET SDS

生物学的特性に関する説明

Technical Params

Product Properties

参考文献

説明

Species	Human
Expression Host	Baculovirus Insect Cells
Tag	GST
Accession Number	P36507
別名	mitogen-activated protein kinase kinase 2, FLJ26075, MKK2, CFC4, PRKMK2, MEK2, MAPKK2
Construction	The Human MAP2K2 (NP_109587.1) (Met 1-Val 400) was fused with the GST tag at the N-terminus.
Protein Purity	> 92 % as determined by SDS-PAGE
分子量	70.7 kDa (predicted)

Endotoxin	< 1.0 EU/μg of the protein as determined by the LAL method.
Formulation	Lyophilized from a solution filtered through a 0.22 μm filter, containing 20 mM Tris, 500 mM NaCl, 2 mM GSH, pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.
Reconstitution	A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.
Stability & Storage	It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at-80℃. For reconstituted proteinsolutions, the solution can be stored at -20°c to -80'c for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
Shipping	In general, Lyophilized powders are shipping with blue ice.
Research Background	Dual specificity mitogen-activated protein kinase kinase 2, also known as MAP kinase kinase 2, MAPKK2, ERK activator kinase 2, MAPK / ERK kinase 2, MEK2 and MAP2K2, is a member of the protein kinase superfamily, STE Ser/Thr protein kinase family and MAP kinase kinase subfamily. MAP2K2 / MEK2 contains one protein kinase domain. MEK1 and MEK2 (also known as MAP2K1 and MAP2K2, respectively) are evolutionarily conserved, dual-specificity kinases that mediate Erk1 and Erk2 activation during adhesion and growth factor signaling. MAP2K1 / MEK1 is a crucial modulator of Mek and Erk signaling and have potential implications for the role of MEK1 and MEK2 in tumorigenesis. MAP2K2 / MEK2 catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. It also activates the ERK1 and ERK2 MAP kinases. Defects in MAP2K2 are a cause of Cardiofaciocutaneous Syndrome (CFC Syndrome) which is characterized by a distinctive facial appearance, heart defects, and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects, and hypertrophic cardiomyopathy.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy

参考文献

1. MacDonald,T.J. et al., 2001, Nat Genet. 29 (2):143-52. 2. Mittal R., et al., 2006, Proc. Natl. Acad. Sci. USA. 103:18574-9. 3. Narumi,Y. et al., 2007, Am J Med Genet A. 143A (8):799-807. 4. Daub H., et al., 2008, Mol. Cell 31:438-448. 5. Catalanotti,F. et al., 2009, Nat Struct Mol Biol. 16 (3):294-303.

Calculator

Reconstitution Calculator

Recombinant Proteins Dilute Calculator

Specific Activity Calculator

bottom

技術サポート

Please read the User Guide of Recombinant Proteins for more specific information.

Keywords

MEK2 Protein, Human, Recombinant (GST) mitogen-activated protein kinase kinase 2 FLJ26075 MKK-2 MEK-2 MEK 2 MKK2 PRKMK-2 MAPKK-2 MAPKK 2 CFC 4 FLJ 26075 FLJ-26075 CFC4 MKK 2 PRKMK2 MEK2 CFC-4 MAPKK2 PRKMK 2 recombinant recombinant-proteins proteins protein